TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04320160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin
Study: NCT04108091

Intervention type: DRUG
Intervention: Treatment for TTR amyloidosis
Description: The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.

Intervention type: DRUG
Intervention: Treatment for TTR amyloidosis
Description: The usual adult dose is 61 mg of tafamidis orally once daily.
Study: NCT03999606

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Training - Choir participation
Description: Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training - Choir participation
Description: Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform.
Study: NCT03542318

Intervention type: OTHER
Intervention: Pulmonary Rehabilitation
Description: A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
Study: NCT02778763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB612
Description: 4 μg CBLB612 SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB612
Description: 4 μg CBLB612 SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02905240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nSTRIDE APS
Description: single intra-articular injection
Study: NCT02778763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01140984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)
Description: Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
Study: NCT04006847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid
Description: Eicosapentaenoic Acid once per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
Study: NCT04026295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Burst Interval Treadmill Training (SBLTT)
Description: SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Locomotor Treadmill Training (TLTT)
Description: TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of \< 6/10.
Study: NCT02087579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole, oral formulation
Description: Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine, oral formulation
Description: Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone, oral formulation
Description: Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone, LAI
Description: Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine, oral formulation
Description: Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, oral formulation
Description: Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, LAI
Description: Risperidone LAI injections will be administered will be administered per the locally approved label indications.
Study: NCT00066807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oophorectomy
Description: Bilateral surgical oophorectomy via laparotomy or laparoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oophorectomy
Description: Bilateral surgical oophorectomy via laparotomy or laparoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian irradiation
Description: Bilateral ovarian irradiation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian irradiation
Description: Bilateral ovarian irradiation.
Study: NCT03250910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Velpatasvir
Description: All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Velpatasvir
Description: All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir
Description: All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir
Description: All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
Study: NCT01352559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: responders
Description: Antidepressants administration for 6 weeks under therapeutic dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-responders
Description: Antidepressants administration for 6 weeks under therapeutic dose
Study: NCT01347398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSG
Description: Sleep study made by PSG (polysomnography)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroMESAM system
Description: Sleep study made by MicroMESAM system
Study: NCT03038178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI plus multi-drug regimen
Description: Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
Study: NCT01645228

Intervention type: RADIATION
Intervention: coronary calcium score measurement

Intervention type: BIOLOGICAL
Intervention: high sensitivity C reactive protein measurement

Intervention type: PROCEDURE
Intervention: ankle brachial index measurement
Study: NCT01015911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-75
Description: SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
Study: NCT01081483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-072
Description: See arm description for more information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description for more information
Study: NCT03727464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstract priming
Description: Patients were primed with a list of abstract during their general anesthesia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstract priming
Description: Patients were primed with a list of abstract during their general anesthesia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concrete priming
Description: Patients were primed with a list of concrete during their general anesthesia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concrete priming
Description: Patients were primed with a list of concrete during their general anesthesia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controls
Description: Patients did not receive any specific stimulation with words during their general anesthesia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controls
Description: Patients did not receive any specific stimulation with words during their general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane general anesthesia
Study: NCT02869295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
Study: NCT02982447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue laser imaging colonoscopy
Description: Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional white light colonoscopy
Description: In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
Study: NCT05466513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial tactile stimulation
Description: Tactile stimulation was given around the face with soft tissue paper for two minutes.
Study: NCT03770000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib, BID orally daily
Study: NCT02646423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prior CD Decision App
Description: The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
Study: NCT03770000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin IV
Study: NCT02751632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and Problem Solving Therapy
Description: Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and Problem Solving Therapy
Description: Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and Problem Solving Therapy
Description: Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Case Management
Description: CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
Study: NCT03425149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: purified inactivated ZIKV vaccine candidate adsorbed on alum
Study: NCT02751632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Case Management
Description: CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
Study: NCT03425149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: purified inactivated ZIKV vaccine candidate adsorbed on alum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: purified inactivated ZIKV vaccine candidate adsorbed on alum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: purified inactivated ZIKV vaccine candidate adsorbed on alum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)
Study: NCT01482871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT01461343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT imaging, functional PET imaging
Description: Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
Study: NCT02751632

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Case Management
Description: CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-monthly monitoring
Description: Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
Study: NCT03108391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme